COVID-19 Clinical Presentation Among HIV-Infected Persons in China: A Systematic Review.
Dayong HuangJiawulan ZunongMenglong LiDan LiJiaJian GongSten H VermundYi-Fei HuPublished in: Current HIV/AIDS reports (2022)
Assuming that HIV-infected persons were at average risk of CoV infection in Wuhan, we estimated HIV-CoV coinfected persons to number 412 (95%CI: 381-442); our review encompassed an estimated 16.7% (69/412) of Wuhan. Men (many of whom reported sex with other men) accounted for 71.1% (54/76) of the cases reported in China. The median age was 48.0 years old (range 24-77, interquartile:37-57). The median CD4+ cell count at the last clinical visit was 421 cells/μL; 83.0% had an undetectable viral load. Among 31 patients with clinical details reported, fatigue (41.9%), respiratory distress (41.9%), and gastrointestinal symptoms (26.7%) were most common. Among the 52 cases reporting COVID-19 clinical severity, 46.2% were severe, 44.2% mild, and 9.6% asymptomatic COVID-19. Late antiretroviral therapy (ART) was reported by 30.4% (7/23) among whom 57.1% (4/7) were confirmed as severe COVID-19. The case fatality rate was 9.1% (3/33). Severe disease and death were less common among persons who took ART prior to the COVID-19 diagnosis. Of 16 reported IL-6 results, 68.7% were within the normal range. Earlier use of ART was associated with a better COVID-19 prognosis with CoV-HIV co-infection reported from China through early 2021, but small sample sizes limit definitive conclusions.
Keyphrases
- hiv infected
- antiretroviral therapy
- coronavirus disease
- sars cov
- respiratory syndrome coronavirus
- human immunodeficiency virus
- hiv positive
- hiv infected patients
- hiv aids
- early onset
- squamous cell carcinoma
- hepatitis c virus
- emergency department
- induced apoptosis
- oxidative stress
- peripheral blood
- depressive symptoms
- cell cycle arrest
- hiv testing
- mesenchymal stem cells
- cell therapy
- rectal cancer
- nk cells